TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

TerrAscend Corp.TSX: TSND.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $31.95M fell 6.6% year over year, ahead of the -10.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • Cost of revenue amounted to 49.8% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -6.6% holds above the trailing-twelve-month pace of -10.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.95M-4.8% QoQ
Last fiscal yearDec 2025
$131.93M-15.8% YoY
LTMMar 2026
$128.47M-10.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.6%——
1 year-15.8%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
131.93M USD
Year-over-year change
-15.8%
4-year CAGR
+4.8%

Cost of Revenue vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.2% is the lowest of 10, against a peer median of +37.3%.
  • Cost of revenue amounts to 49.1% of revenue for TSND.TO, versus a peer median of 53.8%.
TSND.TO Competitors
Cost of Revenue for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$282.6M CAD+116.3%—103.1%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$237.39M CAD+25.3%-20.7%76.4%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$218.14M CAD+40.1%+0.7%68.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$168.32M USD+61.4%+3.7%55.1%
TSND.TOTerrAscend Corp.LTM Mar 2026$128.47M USD-10.2%-13.4%49.1%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$83.17M CAD+37.3%-6.0%52.5%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.35M USD+122.0%+86.8%38.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$12.97M USD+17.0%+63.9%25.5%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$3.99M USD+32.6%+252.4%7.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$281.1K USD+30.3%+7.8%—
Peer median (excluding TSND.TO) —+37.3%+5.7%53.8%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.36M240.45M317.33M306.68M265.12M
Cost of Revenue109.32M203.35M112.49M156.72M131.93M
Gross Profit134.04M119.74M138.02M149.96M133.19M
Gross Margin55.1%49.8%43.5%48.9%50.2%
Research & Development00000
Selling, General & Admin73.71M116.64M112.17M111.33M82.41M
Operating Expenses94.12M150.69M179.56M167.07M87.78M
Depreciation & Amortization13.63M24.6M22.7M22.99M17.51M
EBITDA44.96M(246.52M)(1.03M)6.16M62.92M
EBITDA Margin18.5%-102.5%-0.3%2.0%23.7%
Operating Income31.33M(23.04M)(19.87M)(17.11M)45.41M
Operating Margin12.9%-9.6%-6.3%-5.6%17.1%
Interest Income00000
Interest Expense24.57M37.9M35.11M35.4M36.93M
Other Income / Expenses12.46M(277.92M)(38.97M)(35.13M)(40.34M)
Income Before Tax43.78M(300.95M)(58.83M)(52.23M)5.06M
Pre-Tax Margin18.0%-125.2%-18.5%-17.0%1.9%
Income Tax Expense28.88M(10.46M)23.45M20.44M29.98M
Net Income3.06M(303.96M)(91.1M)(80.23M)(87.74M)
Net Margin1.3%-126.4%-28.7%-26.2%-33.1%
EPS (Basic)0.07(1.31)(0.32)(0.28)(0.29)
EPS (Diluted)0.01(1.31)(0.32)(0.28)(0.29)
Weighted Avg Shares181.06M244.35M279.29M291.51M301.08M
Weighted Avg Shares (Diluted)208.71M244.35M279.29M291.51M301.08M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.